ProShare Advisors LLC grew its position in Illumina, Inc. (NASDAQ:ILMN) by 6.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 154,385 shares of the life sciences company’s stock after acquiring an additional 9,214 shares during the period. ProShare Advisors LLC’s holdings in Illumina were worth $51,216,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in ILMN. Baillie Gifford & Co. grew its holdings in shares of Illumina by 2.8% in the 4th quarter. Baillie Gifford & Co. now owns 17,739,707 shares of the life sciences company’s stock valued at $5,884,971,000 after buying an additional 481,804 shares during the period. Artisan Partners Limited Partnership grew its holdings in shares of Illumina by 50.0% in the 4th quarter. Artisan Partners Limited Partnership now owns 996,268 shares of the life sciences company’s stock valued at $330,502,000 after buying an additional 332,216 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Illumina by 6.3% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,397,671 shares of the life sciences company’s stock valued at $463,663,000 after buying an additional 82,234 shares during the period. Nikko Asset Management Americas Inc. grew its holdings in shares of Illumina by 10.6% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 833,268 shares of the life sciences company’s stock valued at $276,428,000 after buying an additional 80,144 shares during the period. Finally, Wellington Shields & Co. LLC acquired a new position in shares of Illumina in the 4th quarter valued at $23,243,000. 91.08% of the stock is owned by institutional investors.
In related news, SVP Susan H. Tousi sold 200 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $325.00, for a total value of $65,000.00. Following the completion of the transaction, the senior vice president now directly owns 38,465 shares of the company’s stock, valued at approximately $12,501,125. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Oene Mark Van sold 625 shares of the company’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $300.24, for a total transaction of $187,650.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,650 shares of company stock valued at $850,731. Company insiders own 0.38% of the company’s stock.NASDAQ ILMN traded down $1.60 on Friday, reaching $274.42. The company had a trading volume of 1,117,741 shares, compared to its average volume of 1,482,870. The firm has a market capitalization of $40.57 billion, a price-to-earnings ratio of 40.65, a price-to-earnings-growth ratio of 2.61 and a beta of 1.15. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.15 and a current ratio of 6.69. Illumina, Inc. has a 1-year low of $252.43 and a 1-year high of $380.76. The company’s fifty day moving average is $298.12 and its 200-day moving average is $304.80.
Illumina (NASDAQ:ILMN) last announced its earnings results on Wednesday, January 29th. The life sciences company reported $1.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.58 by $0.12. The firm had revenue of $953.00 million during the quarter, compared to analyst estimates of $950.16 million. Illumina had a net margin of 28.27% and a return on equity of 22.34%. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the prior year, the business earned $1.32 EPS. On average, research analysts forecast that Illumina, Inc. will post 6.86 earnings per share for the current year.
Several equities analysts have recently issued reports on ILMN shares. Piper Sandler boosted their price target on shares of Illumina from $341.00 to $370.00 and gave the company an “overweight” rating in a report on Thursday, January 9th. Zacks Investment Research lowered shares of Illumina from a “hold” rating to a “sell” rating and set a $341.00 price target for the company. in a report on Monday, January 20th. Stifel Nicolaus started coverage on shares of Illumina in a report on Thursday, November 14th. They issued a “buy” rating and a $345.00 price target for the company. Wells Fargo & Co decreased their price target on shares of Illumina from $300.00 to $290.00 and set an “underweight” rating for the company in a report on Thursday, January 30th. Finally, Cowen reissued an “outperform” rating and issued a $335.00 price target (up previously from $320.00) on shares of Illumina in a report on Wednesday, December 18th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the stock. Illumina presently has an average rating of “Buy” and an average target price of $335.13.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.